Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of colorectal cancer.

Investigators at Pennsylvania State University have described a novel approach to combat Clostridioides difficile infection using a synthetic microbiome therapy, which offers an alternative to antibiotics and fecal microbiota transplant .

Exposure to high-dose radiation can result in gastrointestinal (GI) acute radiation syndrome, which is characterized by disruption of the mucosal layer, intestinal epithelial barrier dysfunction, and abnormal inflammatory responses. Currently, there are no FDA-approved therapies for the treatment radiation-induced GI injury.

Investigators at Pennsylvania State University have described a novel approach to combat Clostridioides difficile infection using a synthetic microbiome therapy, which offers an alternative to antibiotics and fecal microbiota transplant (FMT). C. diff, the main cause of antibiotic-related diarrhea, is responsible for an estimated half a million infections annually in the U.S.

Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.

Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).

Scientists from the Lebanese American University investigated the role of acetyl-CoA synthetase short chain family member 2 (ACSS2) in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Researchers from The University of Edinburgh have presented data from a study that aimed to investigate the mechanisms behind intestinal stem cell (ISC) dysfunction in ulcerative colitis (UC).